Home Blog

0 17

Patent Number: 8,852,940

Grant date: October 07, 2014
Priority date: April 01, 2009
Estimated expiration date: April 01, 2029
Inventor(s): Blelloch; Robert (San Francisco, CA), Judson; Robert Laird (San Francisco, CA), Subramanyam; Deepa (San Francisco, CA), Melton; Collin Alfred (San Francisco, CA), Wang; Yangming (San Francisco, CA)
Assignee(s): The Regents of the University of California (Oakland, CA)
External link: USPTO website

Abstract:

The methods of the present application describe that introduction of physiologically relevant miRNAs can enhance or modulate somatic cell reprogramming, generating induced pluripotent stem cells (iPS cells). These miRNAs did not further enhance reprogramming in the presence of cMyc. Furthermore, unlike previously described methods of generating iPS cells, such as through the introduction of genetic elements using viruses, the methods of the present invention reduce the risk of activating oncogenes in the iPS cells. The methods of the invention generate iPS cells that can be free of genetic modifications and thus have greater potential for use as therapeutic agents than those generated by existing methods.

0 33

Patent Number: 8,846,914

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Kelleher-Andersson; Judith (Columbia, MD), Johe; Karl K. (Potomac, MD)
Assignee(s): Neuralstem, Inc. (Germantown, MD)
External link: USPTO website

Abstract:

Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.

0 20

Patent Number: 8,846,633

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Chiou; Shih-Hwa (Taipei, TW), Hsu; Han-Shui (Taipei, TW), Cherng; Jong-Yuh (Chiayi County, TW)
Assignee(s): Taipei Veterans General Hospital (Taipei, TW)
External link: USPTO website

Abstract:

The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof.

0 16

Patent Number: 8,846,623

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Yu; John (Taipei, TW), Yu; Alice L. (Taipei, TW), Wu; H. C. (Taipei, TW), Wang; Sheng-Hung (Taichung, TW), Chen; I-Ju (Taipei, TW)
Assignee(s): Academia Sinica (Taipei, TW)
External link: USPTO website

Abstract:

Cancer-targeting peptides having a PX.sub.1LX.sub.2 motif, in which X.sub.1 is His or an amino acid residue with a hydrophobic side chain and X.sub.2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.

0 15

Patent Number: 8,846,402

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Economides; Aris N. (Tarrytown, NY), Murphy; Andrew J. (Croton-on-Hudson, NY), Valenzuela; David M. (Yorktown Heights, NY), Frendewey; David (New York, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee(s): Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
External link: USPTO website

Abstract:

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

0 16

Patent Number: 8,846,400

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Amit; Michal (Misgav, IL), Itskovitz-Eldor; Joseph (Haifa, IL)
Assignee(s): Technion Research & Development Foundation Limited (Haifa, IL)
External link: USPTO website

Abstract:

A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.

0 17

Patent Number: 8,846,396

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Giacomello; Alessandro (Rome, IT), Messina; Elisa (Rome, IT), Battaglia; Massimo (Rome, IT), Frati; Giacomo (Rome, IT)
Assignee(s): Universita Degli Studi Di Roma “La Sapienza” (Rome, IT)
External link: USPTO website

Abstract:

Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs.

0 13

Patent Number: 8,846,395

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Slukvin; Igor I. (Verona, WI), Choi; Kyung-Dal (Madison, WI), Vodyanyk; Maksym A. (Madison, WI)
Assignee(s): Wisconsin Alumni Research Foundation (Madison, WI)
External link: USPTO website

Abstract:

A method for efficient generation of neutrophils, eosinophils, macrophages, osteoclasts, dendritic cells an Langerhans cells from human embryonic stem cells is disclosed.

0 20

Patent Number: 8,846,393

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Peled; Tony (Mevasseret Zion, IL)
Assignee(s): Gamida-Cell Ltd. (Jerusalem, IL)
External link: USPTO website

Abstract:

A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.

0 16

Patent Number: 8,846,392

Grant date: September 30, 2014
Priority date: May 10, 1999
Estimated expiration date: May 10, 2019
Inventor(s): Basile; Lena A. (Tujunga, CA), Gallaher; Timothy Kirk (Arcadia, CA)
Assignee(s): Neumedicines, Inc. (Pasadena, CA)
External link: USPTO website

Abstract:

The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.